

## Appendix B. Antimicrobial susceptibility for MSSA bloodstream infection (England): 2015 to 2018

Year	Antimicrobials Tested	Tested	Proportion* %		
			Susceptible	Intermediate	Resistant
2015	Gentamicin	6.943	98	0	1
2015	Ciprofloxacin	6.250	93	1	6
2015	Vancomycin	5.762	100	0	0
2015	Teicoplanin	4.854	100	0	0
2015	Linezolid	5.506	100	0	0
2015	Erythromycin	5.854	86	0	14
2015	Rifampicin	6.915	98	1	1
2015	Mupirocin	6.600	99	0	1
2015	Fusidic Acid	7.120	87	0	13
2016	Gentamicin	8.261	99	0	1
2016	Ciprofloxacin	7.603	93	1	6
2016	Vancomycin	6.441	100	0	0
2016	Teicoplanin	5.758	100	0	0
2016	Linezolid	6.915	100	0	0
2016	Erythromycin	7.311	85	0	15
2016	Rifampicin	8.196	98	1	1
2016	Mupirocin	7.971	99	1	1
2016	Fusidic Acid	8.341	87	0	13
2017	Gentamicin	8.767	98	0	2
2017	Ciprofloxacin	8.215	93	1	6
2017	Vancomycin	6.714	100	0	0
2017	Teicoplanin	6.123	100	0	0
2017	Linezolid	7.528	100	0	0
2017	Erythromycin	7.948	83	0	17
2017	Rifampicin	8.508	99	1	1
2017	Mupirocin	8.163	99	0	0
2017	Fusidic Acid	8.645	87	0	12
2018	Gentamicin	9.203	98	0	2
2018	Ciprofloxacin	8.637	94	0	5
2018	Vancomycin	6.745	100	0	0
2018	Teicoplanin	6.218	100	0	0
2018	Linezolid	7.970	100	0	0
2018	Erythromycin	8.281	83	0	17
2018	Rifampicin	8.947	99	0	1
2018	Mupirocin	8.522	99	1	0
2018	Fusidic Acid	9.010	87	0	12